AmCad BioMed Balance Sheet Health
Financial Health criteria checks 6/6
AmCad BioMed has a total shareholder equity of NT$477.9M and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$512.6M and NT$34.7M respectively.
Key information
0%
Debt to equity ratio
NT$0
Debt
| Interest coverage ratio | n/a |
| Cash | NT$287.27m |
| Equity | NT$477.95m |
| Total liabilities | NT$34.70m |
| Total assets | NT$512.65m |
Financial Position Analysis
Short Term Liabilities: 4188's short term assets (NT$325.9M) exceed its short term liabilities (NT$24.4M).
Long Term Liabilities: 4188's short term assets (NT$325.9M) exceed its long term liabilities (NT$10.3M).
Debt to Equity History and Analysis
Debt Level: 4188 is debt free.
Reducing Debt: 4188 has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4188 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 4188 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 19.1% each year